Pregnancy Clinical Trial
Official title:
Evaluation of the Education and Counseling Program on Pregnant Women With Risk of Preeclampsia: A Prospective Randomized Controlled Trial
The aim of the study is to evaluate the effect of education and counseling program on healthy lifestyle behaviors, self-efficacy and maternal/neonatal consequences of pregnant women with risk of preeclampsia.
Preeclampsia affects 3% to 5% of pregnancies, and is a pregnancy-specific syndrome; it leads
to maternal, fetal and neonatal morbidity and mortality worldwide especially in developing
countries. If not treated, pregnant woman may have many serious complications, such as
pulmonary edema, eclampsia, stroke, placental abruption, and acute renal diseases . Babies
born to mothers with preeclampsia have an increased risk of low Apgar scores, neonatal
encephalopathy, seizures, neonatal intensive care admission, and neonatal deaths caused by
preterm birth and low gestational age. Preeclampsia also affects the health-related quality
of life negatively.
Since the etiology and pathogenesis of preeclampsia is unclear, it is very important to
investigate the risk factors of preeclampsia to identify the pregnant women in the risk
group, and to ensure more intensive care, observation and follow-ups. The known risk factors
for preeclampsia include primiparity, advanced maternal age, family history of preeclampsia,
previous preeclamptic pregnancy, autoimmune diseases, hypertension, history of thrombophilia,
diabetes, in vitro fertilization, multifetal pregnancy, type I diabetes mellitus or type II
diabetes mellitus and obesity..
It is known that the population has difficulty understanding even basic information related
to health, and especially preeclampsia. Increasing the preeclampsia knowledge of women will
help them to recognize early symptoms, and negative signs of preeclampsia, and may lead them
to seek earlier individual care. Also, it is estimated that appropriate patient education and
counseling for preeclampsia may prevent half of the most serious consequences related to
maternal symptoms. This estimation is supported by a study, that women diagnosed with
preeclampsia receiving proper and timely follow-up had fewer adverse events than those with
delayed diagnosis. Preeclampsia education and counseling subjects may include recommendations
for increasing awareness (preeclampsia signs and signs of danger, follow-up at home) and
lifestyle modifications (physical activity, coping with stress, nutrition advices) to
contribute to the prevention preeclampsia risks.
Although many studies have been carried out on medical treatment and improved outcomes in
women with preeclampsia, there are limited studies about the consequences of education and
counseling of pregnant women with risk of preeclampsia. Therefore, the objective of this
study was to evaluate the effects of maternal and neonatal consequences of an education and
counseling program on at-risk pregnant women.
Trial Design and Participants This study was a single-center, single-blinded, prospective
randomized controlled trial (RCT), parallel-group RCT comparing the effects of a preeclampsia
education and counseling program during pregnancy with standard antenatal care. Participants
were 132 pregnant women with risk of preeclampsia.
We recruited the pregnant women between 12-20 gestational weeks at Obstetrics outpatient
clinic in Ankara Gulhane Education and Research Hospital during routine antenatal care
between May 2015 and March 2016. The eligibility criteria were as follows: having no major
complication related to pregnancy and carrying at least one of the risk factors of
preeclampsia discussed in the literature (American College of Obstetricians and
Gynecologists, 2013; Bilano et al., 2014; Lisonkova and Joseph, 2013). The exclusion criteria
included; having a miscarriage, unable to read or write in Turkish, moving to another city
during the study, and changing the hospital for follow-ups or giving birth.
The sample size was calculated using the G Power 3.1.2 version computer package program
according to the comparison of the self-efficacy-adequacy scale mean difference between the
groups. So that 95% confidence interval and 80% power would be achieved as a mean size of
effect, it was calculated that each group should consist of 45 pregnant women.
Randomization and Participation We selected totally 144 pregnant women at the beginning of
the study. Later, 12 women did not meet eligibility criteria due to the diagnosis of
pregnancy-related complications in the study period (five pregnant women dropped out of the
study, and seven pregnant women planned to give birth in a different hospital). Finally, 132
pregnant women who met the eligibility criteria agreed to participate in this study and we
randomized them as shown in Figure 1 Flow Chart. Eligible women were randomly allocated
(ratio 1:1) into either a control group or study group following an allocation concealment
process using an automatic computer-generated number table. After the randomization process,
13 pregnant women in control group and 19 pregnant women in study group were excluded from
the study due to either moving to another city or having the miscarriage.
Ethics committee permission was obtained from the ethical committee of Ankara Gulhane
Education and Research Hospital with the code 1491-2658-13/16484-303. As they involved human
participants, all procedures were conducted in accordance with the ethical standards of the
Declaration of Helsinki. We informed the women with risk of preeclampsia and who fulfilled
the inclusion criteria about the study procedure, and obtained written informed consent.
Data collection The demographic information, obstetric and general health history were
recorded for both groups at the first assessment. We applied Health Promoting Lifestyle
Profile-II (HPLP II), the Self-Efficacy Scale (SES), pregnant and fetal follow-up forms 4
times during pregnancy. Finally, data of the women and their infants/newborn within
postpartum 48 hours were collected.
In both groups, we recorded necessary information at every follow-up session within
approximately 30 minutes (10 minutes for data collection for control & study group, 20
minutes for education and counseling for study group). We arranged first assessment and
follow-up sessions between 12-20, 23-28, 29-34, 35-40 weeks of gestation.
The first version of the HPLP scale, was developed by Walker et al. in 1987 and revised in
1996 (Walker et al., 1987). The validity and reliability of the HPLP II in Turkish was tested
by Bahar et al. and found to have a high level of validity and reliability (Bahar et al.,
2008). The HPLP II questionnaire consist of 52 items and six dimensions, and it uses a
four-point Likert scale from 1, indicating 'never', to 4, 'routinely'. Possible total scores
on the questionnaire range from 52 to 208. Cronbach's alpha coefficient of the scale was
0.92.
The first version of the SES, developed by Shrer et al. in 1982 and the validity and
reliability of the SES scale in Turkish was tested by Gozum and Aksayan in 1999 (Gözüm and
Aksayan, 1999; Sherer et al., 1982). The SES consist of 23 items and uses a five-point Likert
scale, in which 1 indicates "never defines me" and to 5, "defines me very well". Possible
total scores on the questionnaire range from 23 to 115. Cronbach's alpha coefficient of the
scale was 0.89.
We recorded the information, including presence of edema, feeling of movement of the baby,
physical activity and breathing exercises in both groups on the pregnant and fetal follow-up
form. In addition to these, we measured the blood pressure as well as non-stress test from
the 34th gestation week. Pregnant women in the study group were asked to complete a daily
follow-up form, recording their blood pressure, weight, edema, infant movement, and any
problems. For each follow-up, the forms were collected and new forms were given and necessary
reminders were made about regular filling.
Finally, after birth, in both groups maternal (preeclampsia development status, prenatal and
postnatal blood pressure values and laboratory findings) and neonatal outcomes (first and
fifth APGAR scores, baby's intensive care need, respiratory distress, birth weight and
intra-uterine growth retardation) were collected with the postpartum data collection form,
using information the women themselves, and information in their files.
Interventions Preeclampsia education and counseling program: We prepared a preeclampsia
education booklet in accordance with the literature, (American College of Obstetricians and
Gynecologists, 2013; Kasawara et al., 2012; Lisonkova and Joseph, 2013; You et al., 2012b).
The content of the booklet was guided by the opinion of experts. It was written in easily
understandable language and contained attractive and colorful illustrations. This booklet
contents were definition and risk factors for the development of preeclampsia, maternal and
fetal damages, recommendations for preventing its development (diet, rest, study, exercise,
coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and
edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital,
risk of developing in subsequent pregnancies, and its results. Pregnant women in the study
group were given education and counseling at four times in addition to standard care, using
the preeclampsia education booklet, in a special place. The participants' questions were
answered, and each received a copy of the booklet. Pregnant women in the control group
received standard prenatal care. Necessary reminders were made to attend regular follow-ups
and their questions were answered during these. The researcher allowed participants to call
her for consultations at any time.
Statistical analysis Data were analyzed using IBM SPSS version 22.0 (IBM Corp., Armonk, NY,
USA) and p<0.05 was considered statistically significant. Descriptive statistics for the
variables determined by counting; number and percentage (%); for the variables determined by
measurement, mean±standard deviation (X ± SD), median and minimum-maximum (min-max) values
were used. The conformity of continuous variables to normal distribution was evaluated by
Kolmogorov Smirnov Test. To compare the groups for discrete variables; Chi-Square Test or
Fisher Exact Test, for continuous variables; Student t Test or Mann-Whitney U Test were used.
ANOVA was used for group comparisons for repeated measurements, and Bonferroni Test was used
as post-hoc test. The error level was determined as 0.05 for all analyzes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |